Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm Phase II Clinical Trial to Evaluate the Initial Efficacy and Safety of Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma

NCT04387500 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT04387500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04387500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm Phase II Clinical Trial to Evaluate the Initial Efficacy and Safety of Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2021
Completion date
January 1, 2026
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell, fumarate hydratase deficiency, immunotherapy